# Investigating PKD2 deficiency-associated cardiomyopathies using hESC-cardiomyocytes and bioengineered 3D ventricular cardiac tissue strips

**Authors:** Jingxuan Li, Wentao Peng, Maxwell Kwok, Huanyu Ding, Duan Zhuo, Bimal Gurung, Ishan Raj Lakhani, Hongyan Yu, Ellen N. Poon, Ronald A. Li, Xiaoqiang Yao

PMC · DOI: 10.1038/s41419-026-08639-8 · Cell Death & Disease · 2026-03-25

## TL;DR

This study uses human stem cell-derived heart cells and 3D tissue models to investigate how a kidney disease gene defect causes heart problems.

## Contribution

The study introduces 3D bioengineered ventricular cardiac tissue strips as a novel model for studying PKD2 deficiency-related heart issues in humans.

## Key findings

- Polycystin-2 deficiency reduces heart tissue contractility and alters contraction/relaxation speeds.
- ER stress and reduced sarcoplasmic reticulum Ca2+-ATPase activity are key mechanisms in the observed heart dysfunction.
- Reducing ER stress or boosting Ca2+-ATPase activity partially restores normal heart function in the model.

## Abstract

Autosomal dominant polycystic kidney disease is a highly prevalent hereditary renal disorder caused by mutations in either polycystin-1 or polycystin-2. These patients also develop cardiomyopathies. However, the mechanism of how polycystin-2 defects could lead to cardiomyopathies is poorly understood. Moreover, previous studies using animal models cannot fully represent human cardiomyocyte pathophysiology. Human embryonic stem cells were differentiated into cardiomyocytes. These cardiomyocytes were transduced with viral-based polycystin-2-shRNAs, then mixed with an appropriate amount of human fetal fibroblasts, collagen, and Matrigel, and biofabricated into 3D bioengineered ventricular cardiac tissue strips (hvCTS). We used these 3D hvCTS and 2D human embryonic stem cells-derived cardiomyocytes to recapitulate polycystin-2 deficiency-associated cardiac contractile defects and to explore underlying mechanisms. Knockdown of polycystin-2 decreased the contractile force and slowed down the contraction and relaxation velocities in hvCTS, indicative of contractile malfunction. The underlying mechanisms involved an elevated endoplasmic reticulum stress and a decreased activity of sarcoplasmic reticulum Ca2+-ATPases. Alleviation of endoplasmic reticulum stress by small molecular chaperones 4-phenylbutyrate/tauroursodeoxycholic acid or stimulation of sarcoplasmic reticulum Ca2+-ATPase activity by CDN1163 partially rescued the polycystin-2 deficiency-associated contractile dysfunction in hvCTS. This study used 3D hvCTS and 2D human embryonic stem cells-derived cardiomyocytes as novel disease models to recapitulate PKD2 deficiency-associated contractile defects. We found that knockdown of polycystin-2 induces cardiomyopathies via elevating endoplasmic reticulum stress and decreasing sarcoplasmic reticulum Ca2+-ATPase activity. The results provide novel insights about polycystin-2 deficiency-associated cardiomyopathies in polycystic kidney disease patients.

## Linked entities

- **Genes:** PKD2 (polycystin 2, transient receptor potential cation channel) [NCBI Gene 5311]
- **Chemicals:** 4-phenylbutyrate (PubChem CID 4775), tauroursodeoxycholic acid (PubChem CID 9848818), CDN1163 (PubChem CID 16016585)
- **Diseases:** Autosomal dominant polycystic kidney disease (MONDO:0004691), cardiomyopathies (MONDO:0004994)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** TAT (tyrosine aminotransferase) [NCBI Gene 6898], ATF4 (activating transcription factor 4) [NCBI Gene 468] {aka CREB-2, CREB2, TAXREB67, TXREB}, PRKD1 (protein kinase D1) [NCBI Gene 5587] {aka CHDED, PKC-MU, PKCM, PKD, PKD1, PRKCM}, ACTA1 (actin alpha 1, skeletal muscle) [NCBI Gene 58] {aka ACTA, ASMA, CFTD, CFTD1, CFTDM, CMYO2A}, DDIT3 (DNA damage inducible transcript 3) [NCBI Gene 1649] {aka AltDDIT3, C/EBPzeta, CEBPZ, CHOP, CHOP-10, CHOP10}, HSPA5 (heat shock protein family A (Hsp70) member 5) [NCBI Gene 3309] {aka BIP, GRP78, HEL-S-89n}, TNNT2 (troponin T2, cardiac type) [NCBI Gene 7139] {aka CMD1D, CMH2, CMPD2, LVNC6, RCM3, TnTC}, PKD2 (polycystin 2, transient receptor potential cation channel) [NCBI Gene 5311] {aka APKD2, PC2, PKD4, Pc-2, TRPP2}, PLN (phospholamban) [NCBI Gene 5350] {aka CMD1P, CMH18, PLB}, ATF6 (activating transcription factor 6) [NCBI Gene 22926] {aka ACHM7, ATF6A, ATP6alpha}, BMP4 (bone morphogenetic protein 4) [NCBI Gene 652] {aka BMP2B, BMP2B1, MCOPS6, OFC11, ZYME}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, Ryr2 (ryanodine receptor 2, cardiac) [NCBI Gene 20191] {aka 9330127I20Rik, RYR-2}, Pln (phospholamban) [NCBI Gene 18821] {aka Plb}, ACTN1 (actinin alpha 1) [NCBI Gene 87] {aka BDPLT15}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, PKD1 (polycystin 1, transient receptor potential channel interacting) [NCBI Gene 5310] {aka PBP, PC1, Pc-1, TRPP1, eliosin}, SLC8A1 (solute carrier family 8 member A1) [NCBI Gene 6546] {aka NCX1}, HES2 (hes family bHLH transcription factor 2) [NCBI Gene 54626] {aka bHLHb40}, ATP2A2 (ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2) [NCBI Gene 488] {aka ATP2B, DAR, DD, RHABDO2, SERCA2}, ITPR3 (inositol 1,4,5-trisphosphate receptor type 3) [NCBI Gene 3710] {aka CMT1J, IMD132, IMD133, IP3R, IP3R-3, IP3R3}, NPPA (natriuretic peptide A) [NCBI Gene 4878] {aka ANF, ANP, ATFB6, ATRST2, CDD, CDD-ANF}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, Pkd2 (polycystin 2, transient receptor potential cation channel) [NCBI Gene 18764] {aka C030034P18Rik, PC2, TRPP2}, GPR78 (G protein-coupled receptor 78) [NCBI Gene 27201], INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, XBP1 (X-box binding protein 1) [NCBI Gene 7494] {aka TREB-5, TREB5, XBP-1, XBP2}, RYR2 (ryanodine receptor 2) [NCBI Gene 6262] {aka ARVC2, ARVD2, RYR-2, RyR, VACRDS, VTSIP}
- **Diseases:** death (MESH:D003643), polycystic kidney disease (MESH:D007690), kidney disease (MESH:D007674), PKD deficiency (MESH:C537180), cardiac defects (MESH:D006331), contraction dysfunction (MESH:C536214), SERCA abnormalities (MESH:D000014), contractile deficiency (MESH:D007153), cardiomyopathies (MESH:D009202), ADPKD (MESH:D016891), dilated cardiomyopathy (MESH:D002311), cardiovascular diseases (MESH:D002318), cardiac septal defects (MESH:D006343), polycystin-2 deficiency (MESH:D020803), hypertrophic cardiomyopathy (MESH:D002312), biliary cirrhosis (MESH:D008105), left ventricular hypertrophy (MESH:D017379), renal defects (MESH:C537754), arrhythmia (MESH:D001145), contractile defects (MESH:D000013), urea cycle disorders (MESH:D056806), hvCTS (MESH:D020257), cardiac abnormalities (MESH:D018376), cardiac valvular abnormality (MESH:D006349), Necrosis (MESH:D009336), heart failure (MESH:D006333), hereditary disorder (MESH:D009386), hypoxic (MESH:D002534), cardiomyocyte hypertrophy (MESH:D006984)
- **Chemicals:** pluronic F127 (MESH:D020442), KCl (MESH:D011189), PDMS (MESH:C013830), OCT (MESH:C051883), Mag-fluo-4 (-), AM (MESH:D000576), H7 (MESH:D019307), streptomycin (MESH:D013307), PVDF (MESH:C024865), CDN1163 (MESH:C000609635), nifedipine (MESH:D009543), HEPES (MESH:D006531), NaOH (MESH:D012972), AF647 (MESH:C569686), CaCl2 (MESH:D002122), glycerol (MESH:D005990), amphotericin B (MESH:D000666), EDTA (MESH:D004492), TRIzol (MESH:C411644), eosin (MESH:D004801), 4,6 diamidino-2-phenylindole (MESH:C007293), SDS (MESH:D012967), MgCl2 (MESH:D015636), TUDCA (MESH:C031655), paraformaldehyde (MESH:C003043), PI (MESH:D011419), AP (MESH:D000667), phospholipid (MESH:D010743), methanol (MESH:D000432), TBS (MESH:D013725), 4-PBA (MESH:C075773), penicillin (MESH:D010406), H2O2 (MESH:D006861), H&amp;E (MESH:D006371), phosphate (MESH:D010710), Y27632 (MESH:C108830), caffeine (MESH:D002110), CHIR99021 (MESH:C473711), glucose (MESH:D005947), NaCl (MESH:D012965), ryanodine (MESH:D012433), Fluo-4 (MESH:C409648), DPBS (MESH:C012939), CO2 (MESH:D002245), ascorbic acid (MESH:D001205), Hematoxylin (MESH:D006416), Thapsigargin (MESH:D019284)
- **Species:** Danio rerio (leopard danio, species) [taxon 7955], Rodentia (rodent, order) [taxon 9989], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Escherichia coli (E. coli, species) [taxon 562]
- **Cell lines:** hESCs — Homo sapiens (Human), Telomerase immortalized cell line (CVCL_C464), H1 — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_HA53), H7 — Bos taurus (Bovine), Spontaneously immortalized cell line (CVCL_HG38), hvCTS — Homo sapiens (Human), Transformed cell line (CVCL_YJ37), HEK-293A — Homo sapiens (Human), Transformed cell line (CVCL_0045)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13039962/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13039962/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC13039962/full.md

---
Source: https://tomesphere.com/paper/PMC13039962